8-K 1 a2052009z8-k.txt 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): JUNE 14, 2001 TRANSKARYOTIC THERAPIES, INC. ------------------------------------------------------ (Exact Name of Registrant as Specified in its Charter) DELAWARE ---------------------------------------------- (State or Other Jurisdiction of Incorporation) 000-21481 04-3027191 ----------------------- --------------------------------- (Commission File Number) (IRS Employer Identification No.) 195 ALBANY STREET, CAMBRIDGE, MASSACHUSETTS 02139 ------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (617) 349-0200 -------------------------------------------------- Registrant's Telephone Number, Including Area Code NOT APPLICABLE ------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) Item 5. OTHER EVENTS. On June 14, 2001, Transkaryotic Therapies, Inc. ("TKT") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, TKT's stockholders elected the following persons to serve as directors until the next annual meeting of stockholders or until their successors are duly elected and qualified: Walter Gilbert, Jonathan S. Leff, William R. Miller, Rodman W. Moorhead, III, Richard F Selden, James E. Thomas and Wayne P. Yetter. Attached to this Current Report on Form 8-K and filed as Exhibit 10.33 is a Stockholders' Agreement, dated as of April 12, 2000, by and among TKT and certain other stockholders in TKT Europe 5S AB, a corporation organized under the laws of Sweden. . Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits. 10.33 Stockholders' Agreement, dated as of April 12, 2000, by and among the Registrant and certain other parties listed thereto. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 15, 2001 REGISTRANT TRANSKARYOTIC THERAPIES, INC. By: /s/ Daniel E. Geffken ----------------------------------- Daniel E. Geffken Senior Vice President, Finance and Chief Financial Officer EXHIBIT INDEX EXHIBIT NUMBER DESCRIPTION 10.33 Stockholders' Agreement, dated as of April 12, 2000, by and among the Registrant and certain other parties listed thereto.